GRTX

Galera Therapeutics, Inc. Common Stock

GRTX

Market cap $7.89M

Delisted

GRTX was delisted on the 3rd of June, 2024.

Back to rankings

About: Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Employees: 7

Healthcare Drug Manufacturers - General

Financial journalist opinion

Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.

Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Galera Announces Board Approval of Complete Liquidation and Dissolution

MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024.

Galera Announces Board Approval of Complete Liquidation and Dissolution

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates.

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Galera Adopts Limited Duration Stockholder Rights Agreement

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.

Galera Adopts Limited Duration Stockholder Rights Agreement

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

See News Rankings

Charts implemented using Lightweight Charts™